Carotid Sinus Reaction
Conditions
Interventions
CSR Group: Patients who developed carotid sinus reaction (CSR) intraoperatively or within 24 hours following carotid artery stenting (CAS).:None
Non-CSR Group: Patients who did not develop carotid sinus reaction (CSR) intraoperatively or within 24 hours following carotid artery stenting (CAS).:None
Sponsors
Shengjing Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 80 years; 2. Diagnosed with severe carotid artery stenosis (= 70%, according to the NASCET criteria) via head and neck computed tomography angiography (CTA) between January 1, 2016, and December 31, 2025; 3. Underwent carotid artery stenting (CAS) between January 1, 2016, and December 31, 2025; 4. Received first-time endovascular treatment for the target carotid lesion; 5. Had complete preoperative head and neck CTA data available in raw formats (e.g., DICOM); 6. Presented with stenosis located at the common carotid artery bifurcation or the origin of the internal carotid artery (C1 segment); 7. Possessed complete perioperative vital sign monitoring records, including continuous electrocardiogram (ECG) and blood pressure measurements.
Exclusion criteria
Exclusion criteria: 1. Known history of carotid sinus syndrome or orthostatic syncope; 2. Regular use of medications significantly affecting autonomic nervous function (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, or digitalis) within 3 months prior to surgery, without a washout period of = 5 half-lives before the procedure; 3. Preoperative electrocardiogram (ECG) indicating sinus bradycardia (sustained resting heart rate = 50 beats/min) or a diagnosis of sick sinus syndrome; 4. Severe heart block (second-degree type II or higher atrioventricular block, third-degree atrioventricular block) or pacemaker dependency; 5. History of neck radiotherapy; 6. History of severe trauma or surgical procedures on the ipsilateral neck; 7. Carotid in-stent restenosis (i.e., previous carotid artery stenting at the target lesion); 8. Restenosis following carotid endarterectomy (CEA) (i.e., previous CEA at the target lesion); 9. Unsuccessful stent deployment during the procedure; 10. Perioperative occurrence of acute myocardial infarction, severe arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation), or other major cardiovascular events; 11. Perioperative severe neurological complications, such as intracranial hemorrhage or massive cerebral infarction (infarct volume > 80 mL); 12. Severe allergic reactions to iodine contrast agents during the perioperative period; 13. Severe chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD, GOLD stage 3–4) or dependence on long-term home oxygen therapy; 14. Presence of active malignancies (excluding basal cell carcinoma of the skin or carcinoma in situ) accompanied by involuntary weight loss of = 10% within 6 months, a body mass index (BMI) < 18.5 kg/m² (excluding confounding by edema or ascites), or a confirmed clinical diagnosis of cachexia or severe malnutrition; 15. Substandard CTA image quality due to significant artifacts, severe calcification interference, incomplete scanning coverage, or insufficient resolution that impairs image post-processing and feature extraction (independently assessed by at least two experienced neurosurgeons).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Precision;Recall;F1-score;AUC (area under the receiver operating characteristic curve);Micro-ACC (micro-averaged accuracy); | — |
Countries
China
Contacts
Public ContactYao Yilong
Shengjing Hospital of China Medical University
Outcome results
None listed